A team of scientists led by Georgetown Lombardi Comprehensive Cancer Center researchers has published a study validating that a new test could be key to reducing the cost of caring for patients with bladder cancer while simultaneously relieving some patients of unnecessary treatment.
Physician-scientist Marc E. Lippman, MD, MACP, FRCP, rejoins Georgetown Lombardi Comprehensive Cancer Center as a member of the breast cancer program and will also be a professor in the departments of oncology and medicine at Georgetown University Medical Center.
The third annual Poetry Cafe, hosted by the Georgetown Lombardi Arts and Humanities Program and Mission & Pastoral Care on June 7 in the chapel at MedStar Georgetown University Hospital, provided the hospital community with the opportunity to collectively share their thoughts and experiences through poetry and more.
Definitive results from a large international breast cancer study that included Georgetown Lombardi Comprehensive Cancer Center show that a genetic test can help determine the course of a woman’s treatment and will ultimately spare many women with the most common subtype of breast cancer from receiving chemotherapy.
As associate director of clinical research at Georgetown Lombardi Comprehensive Cancer Center and professor of medical oncology and pharmacology at Georgetown University School of Medicine, Giuseppe Giaccone, MD, PhD, leads a team of researchers in studying thymic carcinoma, also known as cancer of the thymus.
A new collaboration between Georgetown University and the Frederick National Laboratory for Cancer Research in Frederick, Maryland, aims to expand both institutions’ research and training missions in the biomedical sciences.
Family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer Center.
A study led by Michael B. Atkins, MD, deputy director, Georgetown Lombardi Comprehensive Cancer Center, that combined an agent that blocks blood vessel formation with an immunotherapy agent was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer who had not been previously treated.